Clinical Trial Results: pertuzumab

Product Name: pertuzumab
Date of Report: To be Published
Phase: II
A Study to Evaluate the Effect of the Combination of Pertuzumab with Carboplatin-Based Standard Chemotherapy in Patients with Recurrent Ovarian Cancer

Product Name: pertuzumab
Date of Report: 11/1/2005
Phase: II
Open label, phase II, multicenter, randomized study of efficacy and safety for two different doses of a recombinant humanized antibody to HER2 (rhuMAb 2C4) administered every 3 weeks to patients with metastatic breast cancer with low expression of HER2.

Product Name: pertuzumab
Date of Report: 1/1/2006
Phase: II
An open-label, phase II, multicenter study to evaluate the efficacy and safety of a recombinant humanized antibody to HER2 (pertuzumab) administered every 3 weeks to patients with hormone-refractory prostate cancer who have not been treated with chemotherapy.

Product Name: pertuzumab
Date of Report: To be Published
Phase: II
A Study of Pertuzumab in Combination with Herceptin in Patients with Metastatic Breast Cancer

Product Name: pertuzumab
Date of Report: To be Published
Phase: I
A Study of Pertuzumab in Combination With Tarceva (Erlotinib) in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer.

Product Name: pertuzumab
Date of Report: To be Published
Phase: II
A Study of Pertuzumab in Combination with Herceptin in Patients With HER2 Positive Breast Cancer.

Product Name: pertuzumab
Date of Report: To be Published
Phase: III
A Study of Pertuzumab in Combination With Herceptin (Trastuzumab) and Docetaxel in Patients With HER2 Positive Metastatic Breast Cancer.